GlassScriptPhysician profile
Gerald A Feuer
NPI 1275509515
$101,722.31
in general payments reported to CMS, 2019-2025
34 companies · $39K in 2025
The $39K reported for 2025 was more than what 96% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $8,957 · 2021: $8,148 · 2022: $11K · 2023: $3,190 · 2024: $8,865 · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Education: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,450 · Food and Beverage: $2,970 · Travel and Lodging: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,505.00 |
| Education | $17,438.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,450.00 |
| Food and Beverage | $2,969.82 |
| Travel and Lodging | $687.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49,755.95 | 2019-2025 | Lynparza |
| Baxter Healthcare | $43,453.20 | 2019-2025 | Perclot, Tisseel, Floseal |
| Intuitive Surgical, INC. | $5,951.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $353.69 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $295.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $276.29 | 2019-2024 | Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $195.19 | 2020-2024 | Precisetumor |
| Eisai INC. | $181.48 | 2020-2025 | |
| Conmed Corporation | $177.59 | 2019 | |
| Clovis Oncology, INC. | $176.31 | 2019-2020 | |
| Seagen INC. | $156.86 | 2021-2023 | Tivdak |
| Asensus Surgical, INC. | $116.72 | 2019 | |
| Tesaro, INC. | $99.95 | 2019 | |
| Abbvie INC. | $60.99 | 2019-2025 | |
| Becton, Dickinson and Company | $53.16 | 2024 | Arista Ah Flexitip |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $50.16 | 2024 | Integra, Tenoglide, Surgimend |
| Astellas Pharma US INC | $47.84 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $31.47 | 2024 | |
| Kyowa Kirin, INC. | $30.44 | 2020 | |
| Covidien LP | $28.12 | 2019 | |
| Coherus Oncology, INC. | $26.18 | 2020-2021 | |
| Immunogen, INC. | $21.44 | 2023 | Elahere |
| Dilon Technologies, INC. | $18.10 | 2025 | Hemoblast Bellows |
| Ethicon US, LLC | $16.68 | 2020 | |
| Solventum Corporation | $16.54 | 2024 | Prevena |
| Lsi Solutions INC | $16.24 | 2025 | Fornisee |
| Pacira Pharmaceuticals Incorporated | $15.99 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.24 | 2019 | |
| Acell, INC. | $15.18 | 2019 | |
| Zyla Life Sciences, INC. | $15.06 | 2020 | |
| Medtronic, INC. | $14.06 | 2021 | |
| Daiichi Sankyo INC. | $13.38 | 2019 | |
| Convatec INC. | $13.15 | 2021 | |
| Davol INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Feuer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.